Last reviewed · How we verify
Duavive 0.45Mg-20Mg Tablet (duavive-0-45mg-20mg-tablet)
Duavive 0.45Mg-20Mg Tablet is a marketed drug by Pfizer Inc. for moderate to severe vasomotor symptoms associated with menopause. It has a significant commercial presence with $21.2B revenue. The exact mechanism of Duavive is not specified on Wikipedia. Duavive is a treatment option for menopausal symptoms, but its clinical differentiation and pipeline developments are not available. The commercial significance of Duavive is substantial due to its revenue. Further information on Duavive's mechanism and pipeline is required for a comprehensive understanding.
At a glance
| Generic name | duavive-0-45mg-20mg-tablet |
|---|---|
| Sponsor | Pfizer |
| Drug class | estrogen receptor modulator |
| Target | estrogen receptors |
| Phase | FDA-approved |
Approved indications
- Treatment of moderate to severe vasomotor symptoms associated with menopause
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants
- Monoamine oxidase inhibitors (MAOIs)
- Thrombolytics
- Antiplatelet drugs
- Heparin
- Dabigatran
- Rivaroxaban
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duavive 0.45Mg-20Mg Tablet CI brief — competitive landscape report
- Duavive 0.45Mg-20Mg Tablet updates RSS · CI watch RSS
- Pfizer portfolio CI